Method Of Therapeutic Administration Of Dhe To Enable Rapid Relief Of Migraine While Minimizing Side Effect Profile


Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.

Download PDF
Document Preview
Document History
  • Publication: Jan 8, 2019
  • Application: Mar 28, 2017
    US US 201715471334 A
  • Priority: Mar 28, 2017
    US US 201715471334 A
  • Priority: Oct 23, 2015
    US US 201514921860 A
  • Priority: Oct 14, 2014
    US US 201414514322 A
  • Priority: Feb 27, 2012
    US US 201213406391 A
  • Priority: Feb 11, 2008
    US US 6966708 A
  • Priority: Feb 11, 2007
    US US 90085007 P

Download Citation

Sign in to the Lens